Literature DB >> 8200255

Verotoxin induces hemorrhagic lesions in rat small intestine. Temporal alteration of vasoactive substances.

H Tashiro1, S Miura, I Kurose, D Fukumura, H Suzuki, M Suematsu, M Yoshioka, M Tsuchiya, A Kai, Y Kudoh.   

Abstract

E. coli O157:H7 produces a cytotoxin active against Vero cells that has been termed verotoxin. In this study, we demonstrated that local intraarterial injection of verotoxin induced a decrease in blood flow and an increase in hemorrhagic lesions in rat small intestine. Significant increases in the area of hemorrhagic lesions were observed at 120 min after verotoxin injection. These lesions were produced by either verotoxin 1 or 2, but verotoxin 2 produced more extensive lesions. The temporal alteration of vasoactive substances in microcirculatory beds was determined after the administration of culture filtrate of E. coli O157:H7. Tissue-type plasminogen activator activity in regional plasma was significantly elevated as early as 30 min, suggesting that local fibrinolytic activation mediated by microvascular endothelium occurred. There was also early elevation of platelet-activating factor content in the ileal mucosa and its level remained significantly elevated thereafter. Intestinal blood flow, as determined by a laser Doppler flowmeter, started to decrease at about 45 min. The platelet-activating factor antagonist CV6209 was shown to attenuate the decrease in blood flow as well as the development of hemorrhagic lesions, demonstrating that platelet-activating factor is an important mediator for the microcirculatory damage. Accumulation of neutrophils demonstrated by myeloperoxidase activity in the intestinal mucosa and overproduction of oxygen-radicals from neutrophils of the mesenteric veins determined by the luminol-dependent chemiluminescence assay were observed at 60 min, corresponding with the decreased blood flow. Platelet-activating factor may be closely involved in the process of leukocyte accumulation and increased oxygen radical generation, because CV6209 also significantly attenuated these changes.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8200255     DOI: 10.1007/bf02093788

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  38 in total

1.  In vivo visualization of oxyradical-dependent photoemission during endothelium-granulocyte interaction in microvascular beds treated with platelet-activating factor.

Authors:  M Suematsu; I Kurose; H Asako; S Miura; M Tsuchiya
Journal:  J Biochem       Date:  1989-08       Impact factor: 3.387

2.  Infection of gnotobiotic pigs with an Escherichia coli O157:H7 strain associated with an outbreak of hemorrhagic colitis.

Authors:  D H Francis; J E Collins; J R Duimstra
Journal:  Infect Immun       Date:  1986-03       Impact factor: 3.441

3.  Cytopathic effect of verotoxin on endothelial cells.

Authors:  J Kavi; I Chant; M Maris; P E Rose
Journal:  Lancet       Date:  1987-10-31       Impact factor: 79.321

4.  Two distinct toxins active on Vero cells from Escherichia coli O157.

Authors:  S M Scotland; H R Smith; B Rowe
Journal:  Lancet       Date:  1985-10-19       Impact factor: 79.321

5.  Gastric mucosal damage induced by local intra-arterial administration of Paf in the rat.

Authors:  J V Esplugues; B J Whittle
Journal:  Br J Pharmacol       Date:  1988-01       Impact factor: 8.739

6.  Direct cytotoxic action of Shiga toxin on human vascular endothelial cells.

Authors:  T G Obrig; P J Del Vecchio; J E Brown; T P Moran; B M Rowland; T K Judge; S W Rothman
Journal:  Infect Immun       Date:  1988-09       Impact factor: 3.441

7.  CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo.

Authors:  Z Terashita; Y Imura; M Takatani; S Tsushima; K Nishikawa
Journal:  J Pharmacol Exp Ther       Date:  1987-07       Impact factor: 4.030

8.  Vero response to a cytotoxin of Escherichia coli.

Authors:  J Konowalchuk; J I Speirs; S Stavric
Journal:  Infect Immun       Date:  1977-12       Impact factor: 3.441

9.  Escherichia coli O157:H7 strains associated with haemorrhagic colitis in the United States produce a Shigella dysenteriae 1 (SHIGA) like cytotoxin.

Authors:  A O O'Brien; T A Lively; M E Chen; S W Rothman; S B Formal
Journal:  Lancet       Date:  1983-03-26       Impact factor: 79.321

10.  Hemorrhagic colitis associated with a rare Escherichia coli serotype.

Authors:  L W Riley; R S Remis; S D Helgerson; H B McGee; J G Wells; B R Davis; R J Hebert; E S Olcott; L M Johnson; N T Hargrett; P A Blake; M L Cohen
Journal:  N Engl J Med       Date:  1983-03-24       Impact factor: 91.245

View more
  4 in total

1.  Amelioration of chronic inflammation by ingestion of elemental diet in a rat model of granulomatous enteritis.

Authors:  S Tanaka; S Miura; H Kimura; N Ohkubo; Y Tsuzuki; D Fukumura; H Serizawa; I Kurose; M Mori; H Ishii
Journal:  Dig Dis Sci       Date:  1997-02       Impact factor: 3.199

2.  IL-1 is an important mediator for microcirculatory changes in endotoxin-induced intestinal mucosal damage.

Authors:  D Fukumura; S Miura; I Kurose; H Higuchi; H Suzuki; H Ebinuma; J Y Han; N Watanabe; G Wakabayashi; M Kitajima; H Ishii
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

3.  The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice.

Authors:  Tania N Petruzziello-Pellegrini; Darren A Yuen; Andrea V Page; Sajedabanu Patel; Anna M Soltyk; Charles C Matouk; Dennis K Wong; Paul J Turgeon; Jason E Fish; J J David Ho; Brent M Steer; Vahid Khajoee; Jayesh Tigdi; Warren L Lee; David G Motto; Andrew Advani; Richard E Gilbert; S Ananth Karumanchi; Lisa A Robinson; Phillip I Tarr; W Conrad Liles; James L Brunton; Philip A Marsden
Journal:  J Clin Invest       Date:  2012-01-09       Impact factor: 14.808

Review 4.  Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections.

Authors:  J C Paton; A W Paton
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.